Evidence map›Paper›PMID 38844967›Full record

ArticleRespiratory research2024

Resistin predicts disease severity and survival in patients with pulmonary arterial hypertension.

Li Gao, John Skinner, Tanmay Nath, Qing Lin, Megan Griffiths, Rachel L Damico, Michael W Pauciulo, William C Nichols, Paul M Hassoun, Allen D Everett and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Respiratory research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Li GaoDepartment of Medicine, Division of Allergy and Clinical Immunology, Johns Hopkins University School of Medicine, 5501 Hopkins Bayview Circle, Room 3B.65B, Baltimore, MD, 21224-6821, USA. lgao2@jhmi.edu.
John SkinnerDepartment of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, 720 Rutland Avenue, Ross 361, Baltimore, MD, 21287, USA.
Tanmay NathDepartment of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.
Qing LinDepartment of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, 720 Rutland Avenue, Ross 361, Baltimore, MD, 21287, USA.
Megan GriffithsDepartment of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Rachel L DamicoDepartment of Medicine, Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Michael W PauciuloDivision of Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
William C NicholsDivision of Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Paul M HassounDepartment of Medicine, Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Allen D EverettDivision of Pediatric Cardiology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Roger A JohnsDepartment of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, 720 Rutland Avenue, Ross 361, Baltimore, MD, 21287, USA. rajohns@jhmi.edu.

Funding

National Biological Sample and Data Repository for PAHR24HL105333 · NHLBI · CINCINNATI CHILDRENS HOSP MED CTR · PI NICHOLS, WILLIAM C · 2012 to 2016
$10.1M
REGULATION OF NO SIGNALING IN PULMONARY VASCULATURER01HL039706 · NHLBI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI JOHNS, ROGER A · 1993 to 2006
$2.4M
DAMP Signaling Mediates HIMF-induced Pulmonary HypertensionR01HL138497 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI JOHNS, ROGER A · 2018 to 2021
$1.8M
Targeting resitin and RELM-beta to treat pulmonary hypertensionP50HL107182 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI JOHNS, ROGER A · 2011 to 2012
$983k
NHLBI NIH HHS P50 HL107182NHLBI NIH HHS R01 HL039706NHLBI NIH HHS R01 HL138497NHLBI NIH HHS R24 HL105333NIH HHS R01HL039706, R01HL138497, P50HL107182, R24HL105333
6 · The paper itself

Abstract

backgroundAbnormal remodeling of distal pulmonary arteries in patients with pulmonary arterial hypertension (PAH) leads to progressively increased pulmonary vascular resistance, followed by right ventricular hypertrophy and failure. Despite considerable advancements in PAH treatment prognosis remains poor. We aim to evaluate the potential for using the cytokine resistin as a genetic and biological marker for disease severity and survival in a large cohort of patients with PAH.

methodsBiospecimens, clinical, and genetic data for 1121 adults with PAH, including 808 with idiopathic PAH (IPAH) and 313 with scleroderma-associated PAH (SSc-PAH), were obtained from a national repository. Serum resistin levels were measured by ELISA, and associations between resistin levels, clinical variables, and single nucleotide polymorphism genotypes were examined with multivariable regression models. Machine-learning (ML) algorithms were applied to develop and compare risk models for mortality prediction.

resultsResistin levels were significantly higher in all PAH samples and PAH subtype (IPAH and SSc-PAH) samples than in controls (P < .0001) and had significant discriminative abilities (AUCs of 0.84, 0.82, and 0.91, respectively; P < .001). High resistin levels (above 4.54 ng/mL) in PAH patients were associated with older age (P = .001), shorter 6-min walk distance (P = .001), and reduced cardiac performance (cardiac index, P = .016). Interestingly, mutant carriers of either rs3219175 or rs3745367 had higher resistin levels (adjusted P = .0001). High resistin levels in PAH patients were also associated with increased risk of death (hazard ratio: 2.6; 95% CI: 1.27-5.33; P < .0087). Comparisons of ML-derived survival models confirmed satisfactory prognostic value of the random forest model (AUC = 0.70, 95% CI: 0.62-0.79) for PAH.

conclusionsThis work establishes the importance of resistin in the pathobiology of human PAH. In line with its function in rodent models, serum resistin represents a novel biomarker for PAH prognostication and may indicate a new therapeutic avenue. ML-derived survival models highlighted the importance of including resistin levels to improve performance. Future studies are needed to develop multi-marker assays that improve noninvasive risk stratification.

Indexed as

ResistinSeverity of Illness IndexAdultAgedBiomarkersCohort StudiesFemaleHumansHypertension, PulmonaryMaleMiddle AgedPolymorphism, Single NucleotidePredictive Value of TestsPulmonary Arterial HypertensionSurvival RateBiomarkersResistinRETN protein, humanBiomarkerMachine learningPulmonary arterial hypertensionResistinSingle nucleotide polymorphismSNP

Identifiers

PMID38844967
PMCPMC11154998

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.